Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01450943 · ClinicalTrials.gov registry record · Phase 3
VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic
A Phase 3 study of Diabetic Foot Ulcer, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT01450943: Completed Phase 3 study of Diabetic Foot Ulcer, sponsored by VA Office of Research and Development.
NCT01450943 is a Phase 3 study of Diabetic Foot Ulcer that has completed, run by VA Office of Research and Development. The registered enrollment target is 120 participants, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01450943, a Phase 3 study of Diabetic Foot Ulcer, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to assess the effectiveness of cellular dermal replacement tissue vs. non-viable extracellular matrix (ECM) for the treatment of non-healing diabetic foot ulcers. Our hypothesis is that these devices are of equal efficacy.
Primary Outcome
The primary outcome of interest is defined as the wound healed completely on or before visit 15, regardless of a later recurrence.
Conditions Studied
Interventions
- DEVICE SECONDARY dressing gauze and tape
- PROCEDURE debridement, irrigation
- DEVICE Dermagraft
- DEVICE Oasis
Study Locations (1)
California
- VA Northern California Health Care System, Mather, CA - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2011-10-01 |
| Est. Completion | 2018-04-04 |
| Phase | Phase 3 |
What the finished NCT01450943 record still lists
NCT01450943 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 4 interventions - of which SECONDARY dressing gauze and tape is the first listed.
NCT01450943 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01450943 about?
NCT01450943 is a clinical study titled "VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic". The primary objective of this study is to assess the effectiveness of cellular dermal replacement tissue vs. non-viable extracellular matrix (ECM) for the treatment of non-healing diabetic foot ulcers. Our hypothesis is that these devices are of equal efficacy.
What is the current status of trial NCT01450943?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2011-10-01. Estimated completion is 2018-04-04.
What conditions does trial NCT01450943 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer.
What interventions are being tested in trial NCT01450943?
The interventions under investigation include: SECONDARY dressing gauze and tape (DEVICE), debridement, irrigation (PROCEDURE), Dermagraft (DEVICE), Oasis (DEVICE).
Who is sponsoring clinical trial NCT01450943?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01450943 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01450943's enrollment target sits among peer trials
120 32nd of 67 higher than 34 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
RECRUITING · Phase 4
-
Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.
RECRUITING
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI